文献速递功能神经外科

抗凝治疗患者行脑深部电刺激电极植入的安全性评估

Safety of Deep Brain Stimulation Lead Placement on Patients Requiring Anticlotting Therapies.
PubMed 文献 · World Neurosurg · 2020-10-15

本研究基于2011至2020年前瞻性数据库,回顾性分析226例患者共267次DBS电极及电池植入/更换手术,其中89例(33%)术前停用1种抗凝药、2例(0.7%)停用2种。抗凝药停用患者与未用药患者不良事件率无差异(χ2[1]=1.523,P=0.2171),无血栓相关后遗症,3例出血均见于未用药患者,提示按既定方案停用抗凝药后行DBS电极植入未增加并发症风险。

要点

  • 抗凝药停用患者行DBS电极植入的不良事件率与未用药者无显著差异。
  • 本组无血栓相关后遗症,3例出血均发生于未使用抗凝药患者。
  • 研究方案在平衡出血与血栓栓塞风险方面显示可行。

核心结论

  • 常规使用抗凝药并停药后行DBS电极植入未增加并发症风险。
  • 本中心方案在平衡出血与血栓栓塞事件风险方面是成功的。

研究设计与样本

  • 基于2011至2020年机构审查委员会批准的前瞻性结局数据库进行回顾性分析。
  • 纳入连续接受DBS电极和电池植入/更换手术的患者,共226例、381个电极植入、267次手术。
  • 回顾记录术后90天内发生的不良事件。

主要发现

  • 267次手术中176次(66%)患者未使用抗凝药,89次(33%)使用1种药物,2次(0.7%)使用2种药物。
  • 抗凝药使用与未使用患者不良事件率无差异(χ2[1]=1.523,P=0.2171)。
  • 无患者发生血栓相关后遗症,3例出血均见于未使用抗凝药患者。

临床怎么用

  • 对常规使用抗凝药的患者,可按既定停药方案安全实施DBS电极植入。
  • 术后90天内需关注出血与血栓栓塞事件,但本组数据显示风险未显著增加。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Limited studies exist to support the safety of performing neuromodulation surgeries in patients whose anticlotting medication has been held. Here, we assess the safety of performing deep brain stimulation (DBS) in this patient population. METHODS: All consecutive DBS patients who underwent lead and battery placement/revision at our institution between 2011 and 2020 were included in this Institutional Review Board-approved prospective outcomes database. We retrospectively recorded adverse events occurring within 90 days of surgery. RESULTS: The study included 226 patients who underwent 381 lead placements in 267 surgeries. Of the 267 surgeries included in this study, 176 (66%) were performed on patients not on anticoagulants and 89 (33%) cases were on patients on 1 drug. Two (0.7%) cases involved a patient taking 2 drugs. A total of 49 adverse events were seen. Thirteen occurred in patients taking anticoagulants. There was no difference in adverse event rate between patients on anticlotting medication and those not (χ2 [1] = 1.523, P = 0.2171). No clot-related sequelae occurred in any patient. Three hemorrhages occurred, all in patients not on anticoagulants. CONCLUSIONS: We found no increased risk of complications in patients routinely on anticlotting medication undergoing DBS lead placement. We show that our protocol was successful in balancing increased risks of bleeding and of thromboembolic events in this patient group.

来源:World Neurosurg,查看原文。版权归原作者所有。

引用

  1. Topp G, Ghulam-Jelani Z, Chockalingam A, et al. Safety of Deep Brain Stimulation Lead Placement on Patients Requiring Anticlotting Therapies. World Neurosurg. 2020. PMID: 33068799. doi:10.1016/j.wneu.2020.10.047

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。